News

Phase II ‘basket’ clinical trial of PB272 (neratinib) in patients with tumors harboring HER2 or HER3 mutations results were declared by Puma Biotechnology as published in the journal…
Read More...

Vertex Pharmaceuticals selected VX-659 and VX-445 for Phase 3 development as part of two different triple combination regimens fir people with cystic fibrosis. Phase 2 data was…
Read More...

Ferring Pharmaceuticals affirmed that the U.S FDA has sanctioned ZOMACTON for injection 5 mg and 10 mg recombinant human growth hormone implied for replacement of GH in adults with GH…
Read More...

QIAGEN N.V forays into an agreement to acquire STAT-Dx to develop the next generation of multiplex diagnostics for one-step, fully integrated molecular analysis of common syndromes…
Read More...

Authentidate Holding Corp asserted completion of its Corporate name change to Aeon Global Health Corp with  effect immediately. The name change is part of the company's broader…
Read More...

Global provider of cloud-based technology and data analytics for clinical research, Medidata and Syapse partner to transform Oncology Clinical Trials for the age of precision medicine.…
Read More...

Clinical stage biopharmaceutical company focused on developing pharmaceutical therapies based on its proprietary Accordion Pill  platform technology, Intec Pharma appointed R. Michael…
Read More...

SkylineDX affirmed foraying into a strategic collaboration to curate novel diagnostic tests to enhance clinical decision making for melanoma patients. The Joint development agreement…
Read More...

Novartis declared results from ELIANA Clinical Trial of kymriah in refractory pediatric and young adult patients with B-cell acute lymphoblastic leukemia.  Kymriah claimed to become one…
Read More...

Perrigo Company declared having sought tentative U.S FDA approval for the generic version of Soolantra cream,1%. Soolantra cream implied for the treatment of inflammatory lesions of…
Read More...

CorePharma acquired by Investor Group, its facilities and equipment in Middlesex, NJ from Impax Laboratories. Financial terms of the acquisition were not disclosed. The acquisition does…
Read More...

Microbiome comapany developing customized phage therapies , BiomX Ltd. declared that it has sought sub-license from JSR Corporation a set of bacterial targets for the development and…
Read More...

Clinical-stage biotechnology company,devoted to treating inflammation and inborn errors of metabolism, Aldeyra Therapeutics enrolled first patient in a Phase 2b Clinical Trial of …
Read More...

Upsher-Smith Laboratories, LLC  declared that it sought U.S Food and Drug Administration's approval for new drug application (ANDA) for Bumetanide Tablets, USP, 0.5 mg, 1 mg, and 2 mg,…
Read More...

Industry leader in orthopaedic devices using advanced functional materials, MedShape declared successful performance of first surgeries using DynaNail XL TTC Fusion System.  The…
Read More...

Mallinckrodt plc affirmed enrolling first patient in the company's Phase 4, multi center, randomized, double-blind, placebo-controlled pilot study to facilitate evaluation of the…
Read More...

U.S  Food and Drug Administration conceded to Multi  Radiance Medical's MR4 Laser technology for neck and shoulder pain relief under the Product Classification NHN. MR4 Laser technology…
Read More...

Takeda Pharmaceutical company Limited asserted that the U.S Food and Drug Administration has extended Fast Track designation to TAK-426 i.e Takeda's Zika virus vaccine candidate. …
Read More...

European Organisation for Research and Treatment of Cancer (EORTC) and Foundation Medicine collaborate to ascertain eligibility of patients for oncology clinical Trials of  Foundation…
Read More...

In a bid to commercialize NERLYNX, Puma Biotechnology and Medison Pharma have forayed into an exclusive licensing agreement in Israel as it is currently not approved for…
Read More...